Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Non-ST elevation acute coronary syndrome (NSTEACS) presents a high risk of ischemic events.
• The optimal antithrombotic regimen for NSTEACS remains undefined.
• Standard antiplatelet therapy may not fully mitigate ischemic risks.

Purpose of the Study:

• To evaluate the effect of cilostazol on platelet aggregation and PAI-1 levels in NSTEACS patients.
• To assess the efficacy and safety of adding cilostazol to standard antiplatelet therapy.
• To determine if cilostazol improves clinical outcomes in NSTEACS.

Main Methods:

• A randomized controlled trial involving 40 NSTEACS patients treated conservatively.
• Patients received either cilostazol (100 mg b.i.d.) or placebo for 7 days, alongside aspirin and clopidogrel.
• Primary endpoints included changes in agonist-induced platelet aggregation and serum PAI-1 levels after 7 days; safety and clinical outcomes were assessed at 7 and 30 days.

Main Results:

• Triple therapy with cilostazol significantly reduced ADP and collagen-induced platelet aggregation compared to dual therapy (p=0.003 and p=0.04, respectively).
• No significant difference was observed in serum PAI-1 levels between the groups (p=0.42).
• The composite endpoint of recurrent ischemia, myocardial infarction, intervention, or death occurred in 4 patients in the cilostazol group versus 7 in the placebo group (p=0.48) at 30 days.

Conclusions:

• Cilostazol demonstrates additional platelet aggregation inhibition when combined with aspirin and clopidogrel in NSTEACS patients.
• While cilostazol enhances antiplatelet effects, its impact on PAI-1 and major adverse cardiovascular events requires further investigation.
• The findings suggest a potential role for cilostazol in managing NSTEACS, warranting larger studies.